Vimal Mehta | Chief Executive Officer & Founder |
Richard Steinhart | Senior Vice President and Chief Financial Officer |
Matt Wiley | Chief Commercial Officer |
Robert Risinger | Chief Medical Officer, Neuroscience |
Frank Yocca | Chief Scientific Officer |
Vincent O’Neill | Senior Vice President & Chief Medical Officer, Oncology |
Greg Harrison | Bank of America |
Robyn Karnauskas | Truist Securities |
Sumant Kulkarni | Canaccord |
Colin Bristow | UBS |
Richard Allen | Mizuho Securities |
Ram Selvaraju | H.C. Wainwright |
Corinne Jenkins | Goldman Sachs |
Good morning and welcome to the BioXcel Therapeutics Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] After the presentation, there will be a question-and-answer session. [Operator Instructions] Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.